Ethylene oxide (EO) residue testing is a mandatory quality control and biocompatibility requirement for medical catheters sterilized with EO gas. Based on ISO 10993-7 and its Chinese counterpart GB/T 16886.7, this testing confirms that residual ethylene oxide and ethylene chlorohydrin remain below patient-safe limits before product release. This article explains the applicable standards, test samples, analytes, analytical methods, and frequently asked questions related to EO residual testing for medical catheters.
Technical Overview
Ethylene oxide sterilization is one of the most widely used terminal sterilization processes for medical catheters because it operates at low temperature and is compatible with heat- and moisture-sensitive polymers such as PVC, polyurethane, silicone, polyethylene, and thermoplastic elastomers. However, EO is a toxic, mutagenic, and carcinogenic alkylating agent, and its degradation or reaction by-products, mainly ethylene chlorohydrin (ECH, 2-chloroethanol) and ethylene glycol (EG), also present toxicological risks. Because catheters contact mucous membranes, internal tissues, and the bloodstream, residual sterilants can migrate into patients and cause local irritation, hemolysis, sensitization, or systemic toxicity.
ISO 10993-7 (Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals) and the Chinese national standard GB/T 16886.7 establish allowable limits for EO and ECH residues according to the cumulative contact duration of the device. Demonstrating compliance with these limits is an essential element of the biological safety evaluation required for regulatory submissions worldwide, including NMPA registration in China, FDA submissions in the United States, and conformity assessment under the EU MDR. The allowable limits per device are:
- Limited contact (up to 24 hours): EO not more than 4 mg and ECH not more than 9 mg
- Prolonged contact (24 hours to 30 days): EO not more than 2 mg and ECH not more than 2 mg as a 30-day average daily dose
- Permanent contact (more than 30 days): EO not more than 0.1 mg/day and ECH not more than 2 mg/day on a lifetime average basis
Residues are influenced by polymer type, catheter geometry, packaging permeability, sterilization cycle parameters, aeration time, and storage temperature. Therefore, residual testing must be integrated into sterilization validation under ISO 11135 and monitored during routine production.
Testing Samples
Finished Sterile Catheter Products
Terminally sterilized, single-use catheters in their final primary packaging are the principal test articles. Typical product categories include urinary (Foley) catheters, central venous catheters, peripherally inserted central catheters, hemodialysis catheters, endotracheal tubes, suction catheters, nasogastric feeding tubes, wound and drainage catheters, and intravenous infusion catheters. Samples must be representative of routine production and should be tested after completion of the specified aeration period defined in the sterilization specification.
Catheter Components and Raw Materials
Polymer tubing, shafts, balloons, hubs, connectors, coatings, adhesives, and packaging materials may be tested individually to identify EO absorption sources, compare material sorption behavior, and support material or supplier changes within a validated design.
Product Families and Worst-Case Configurations
When a range of catheter sizes or models shares identical materials, construction, and sterilization process, a product-family rationale may justify selecting the worst-case configuration for testing, such as the largest polymer mass, thickest wall, smallest lumen-to-mass ratio, or the least permeable packaging configuration.
Process Validation and Stability Samples
Samples generated during sterilization and aeration validation runs, as well as units pulled at defined intervals during shelf-life studies, are tested to construct degassing curves and confirm that residues remain within limits throughout the labeled expiry period.
Testing Items
The core scope of EO residual testing for medical catheters includes the following items, each reported on a per-device basis and, where applicable, normalized to device mass:
- Ethylene oxide (EO) residual content, in mg per device
- Ethylene chlorohydrin (ECH, 2-chloroethanol) residual content, in mg per device
- Ethylene glycol (EG) residual content, where risk assessment or the standard requires evaluation
- Simulated-use extraction results, reflecting clinically realistic residue delivery to the patient
- Exhaustive extraction results, representing the total residual burden retained in the device
- Aeration and degassing curve data, defining the minimum post-sterilization holding time before release
Testing Methods
Gas chromatography (GC) is the reference analytical platform for EO residual determination, as specified in ISO 10993-7 and GB/T 16886.7. Because EO is volatile and residues continue to dissipate after sterilization, strict control of sample handling, sealing, storage temperature, and analysis timing is essential to obtain representative results.
Sample Extraction Strategies
ISO 10993-7 defines two complementary extraction approaches. Simulated-use extraction exposes the catheter to an extraction medium under conditions that mimic clinical use, capturing the residue fraction actually delivered to the patient. Exhaustive extraction repeatedly extracts the device until residues are depleted, quantifying the total residual load retained by the polymer. The choice depends on device contact duration, intended use, and the conservatism required by the risk assessment.
EO Determination by Headspace Gas Chromatography
EO is quantified by static headspace GC, typically with flame ionization detection (GC-FID). The catheter sample is cut, weighed, sealed in a headspace vial, and equilibrated at a controlled elevated temperature so that residual EO partitions into the headspace for injection. Quantification is performed against multipoint calibration curves prepared from EO standard solutions, with results expressed in mg per device.
ECH and EG Determination
ECH is far less volatile than EO and is generally determined by liquid extraction of the catheter in a suitable solvent such as water or acetone, followed by GC analysis using FID, electron capture detection, or mass spectrometric confirmation (GC-MS). EG may be quantified from the same extract using GC or ion chromatography when required. Derivatization techniques may be applied to improve sensitivity and chromatographic behavior.
Method Validation and Quality Control
Validated methods must demonstrate specificity, linearity across the calibration range, accuracy and recovery, repeatability, and adequately low limits of detection and quantitation relative to the applicable limits. Quality controls include replicate sample analysis, spiked recovery checks, blanks, and calibration verification. Testing is typically performed in laboratories accredited to ISO/IEC 17025, either in-house or by accredited third-party laboratories, ensuring data are accepted for regulatory submission.
Applications
EO residual testing for medical catheters supports the full product lifecycle, from development to routine market supply. Key applications include:
- Regulatory registration and submission dossiers for NMPA, FDA, and EU MDR, where residue data form part of the biological safety documentation
- Validation of EO sterilization cycles and aeration parameters in accordance with ISO 11135
- Routine batch release testing and periodic verification of residual control after process qualification
- Shelf-life and stability studies confirming residues remain compliant at the end of the labeled expiry date
- Change control for material, supplier, packaging, or cycle modifications that may affect residue uptake or dissipation
- Failure investigations and risk assessments following out-of-specification residual findings
FAQ
Why must medical catheters be tested for EO residuals?
EO and its by-products are toxic and carcinogenic. Catheters contact vulnerable tissues and the circulatory system, so residual sterilants can migrate into patients at harmful levels. Testing verifies that residues comply with the allowable limits in ISO 10993-7 and GB/T 16886.7 before devices are released.
What are the acceptance limits for EO and ECH residues?
For devices with patient contact of 24 hours or less, the limits are 4 mg for EO and 9 mg for ECH per device. For contact from 24 hours to 30 days, the limits are 2 mg for EO and 2 mg for ECH as 30-day average daily doses. For permanent-contact devices, EO is limited to 0.1 mg/day and ECH to 2 mg/day.
When should samples be tested after sterilization?
Samples are tested after the minimum aeration or degassing time specified for the product, because residues decline continuously after sterilization. Testing is normally scheduled at the point of product release, and degassing curves generated during validation define the earliest allowable release time.
How many catheter samples are required?
Typical protocols analyze three to five independently manufactured units per product or product family per test point. The exact number depends on the validation protocol, statistical rationale, and regulatory expectations.
Can EO and ECH be measured in the same analysis?
EO is best determined by headspace GC because of its high volatility, while ECH requires liquid extraction followed by GC or GC-MS due to its low volatility. The two analytes are therefore usually quantified using separate, complementary procedures on the same test units.
Do all EO-sterilized catheters need residual testing?
Yes. Every catheter sterilized with EO must be evaluated for residual compliance, either through direct testing of the device or, where scientifically justified, through a documented product-family rationale in which worst-case configurations are tested on behalf of the family.